Share
Glucagon-like peptide-1 receptor agonists (GLP‑1 Ras) — such as semaglutide and liraglutide — are celebrated for producing weight-loss results comparable to bariatric surgery, improving glucose control, and reducing cardiovascular risk. Yet new questions are surfacing about what users may be losing, besides fat. A recent narrative review in the Journal of Clinical Endocrinology & Metabolism warns...
Share
Endocrine Society experts encouraged more widespread screening for primary aldosteronism – a common hormonal cause of high blood pressure — in a new Clinical Practice Guideline presented during a packed session on the last day of ENDO 2025 in San Francisco and appearing in this month’s Journal of Clinical Endocrinology & Metabolism. William F. Young,...
Share
A groundbreaking global international analysis published in eBioMedicine (via The Lancet) has quantified the worldwide cardiovascular toll attributed to di-2-ethylhexyl-phthalate (DEHP) — a common plastic additive used to soften the plastic polyvinyl chloride (PVC), which is found in everyday objects such as vinyl records, pipes, and cosmetics. In 2018 alone, DEHP exposure accounted for an...
Share
Many primary aldosteronism cases remain undiagnosed and untreated Endocrine Society experts encouraged more widespread screening for a common hormonal cause of high blood pressure known as primary aldosteronism in a new Clinical Practice Guideline released today. “Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline” was published online and is being presented at ENDO 2025, the...
Share
A third generation of the latest cholesterol-lowering medication — PCSK9-inhibitors — will soon be available for patients with homozygous familial hypercholesterolemia (HoFH), according to a January 24 article in The Lancet Diabetes & Endocrinology. Affecting approximately 30,000 individuals worldwide, HoFH is a rare but serious genetic disorder in which patients have markedly elevated levels (>10...
Share
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating...
Share
Higher levels of HDL-C—known as the “good cholesterol”—have been shown to correlate with heightened risk for Alzheimer’s disease, according to a study recently published in The Journal of Clinical Endocrinology & Metabolism. Once women reach the menopause transition, it’s a matter of the quality, rather than quantity, of the total cholesterol carried by HDL particles circulating in a...
Share
A paper recently published in Endocrine Reviews takes a look at the cardiometabolic risk in patients with congenital adrenal hyperplasia (CAH), since patients with CAH who are being treated still face numerous complications and increased mortality. The authors of the review (Krysiak et al) write that the aim of their article is to create an...
